PegBio Co., Ltd. (HKG:2565)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
60.70
-1.30 (-2.10%)
Last updated: Mar 6, 2026, 3:30 PM HKT
Market Cap23.50B
Revenue (ttm)n/a
Net Income-242.62M
EPS-0.66
Shares Out391.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume191,950
Average Volume254,398
Open61.00
Previous Close62.00
Day's Range59.35 - 62.95
52-Week Range8.68 - 77.00
Betan/a
RSI41.22
Earnings DateMay 18, 2026

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 58
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2565
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements